Nirogacestat
Brand names: Ogsiveo · Active ingredient: Nirogacestat
In short: OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.
What is Nirogacestat used for?
OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.
Nirogacestat dosage
The recommended dosage of OGSIVEO is 150 mg administered orally twice daily until disease progression or unacceptable toxicity. OGSIVEO may be taken with or without food.
Instruct patients to swallow OGSIVEO tablets whole and not to break, crush, or chew prior to swallowing.
If a patient vomits or misses a dose, instruct the patient to take the next dose at its scheduled time.
The recommended dose modifications for OGSIVEO for selected severe adverse reactions are summarized in Table 1 . For other severe adverse reactions, life-threatening adverse reactions, or persistent intolerable Grade 2 adverse reactions, withhold drug until resolved to Grade ≤ 1 or baseline. Only restart at a dosage of 100 mg twice daily after considering the potential benefit and likelihood of recurrence of the adverse reaction. Permanently discontinue OGSIVEO for recurrence of severe or life-threatening adverse reaction upon rechallenge at the reduced dose.
Adverse Reaction | Severity | OGSIVEO
Dosage Modifications
Diarrhea persisting for ≥ 3 days despite maximal medical therapy
| Grades 3 or 4 | Withhold OGSIVEO until resolved to Grade ≤ 1 or baseline, then restart at a dosage of 100 mg twice daily.
Increased ALT or AST
| Grade 2(≥ 3 to 5 × ULN) | Withhold OGSIVEO until ALT, AST, or both are resolved to < 3 × ULN or baseline, then restart at a dosage of 100 mg twice daily.
Grades 3 or 4(> 5 × ULN) | Permanently discontinue.
Hypophosphatemia persisting for ≥ 3 days despite maximal replacement therapy
| Grades 3 or 4 | Withhold OGSIVEO until resolved to Grade ≤ 1 or baseline, then restart at a dosage of 100 mg twice daily.
Hypokalemia despite maximal replacement therapy
| Grades 3 or 4 | Withhold OGSIVEO until resolved to Grade ≤ 1 or baseline, then restart at a dosage of 100 mg twice daily.
Anaphylaxis or other severe hypersensitivity reaction
| Grades 3 or 4 | Permanently discontinue.
How to take Nirogacestat — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Diarrhea
Advise patients that OGSIVEO can cause diarrhea, which may be severe, and to contact their healthcare provider for sustained diarrhea that does not respond to supportive care .
Ovarian
Toxicity
Advise females of reproductive potential that OGSIVEO can cause ovarian toxicity and impair fertility, and that these effects may continue following discontinuation of OGSIVEO. Advise patients to tell their healthcare provider if they experience symptoms of ovarian toxicity, including hot flashes or menstrual irregularities .
Liver Toxicity
Advise patients that OGSIVEO can cause ALT or AST elevations, and that their healthcare provider should monitor liver transaminase levels regularly .
Non-Melanoma Skin Cancers
Advise patients that OGSIVEO can cause new non-melanoma skin cancers, that they will be monitored for these, and to contact their healthcare provider for any new or changing lesions on their skin
.
Electrolyte Abnormalities
Advise patients that OGSIVEO can cause hypophosphatemia and/or hypokalemia which may require phosphate and/or potassium supplementation. …
Warnings & precautions
Do not take this medicine if: None.
Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO .
In DeFi, diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients. Median time to first diarrhea event for patients treated with OGSIVEO was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications. Modify dose as recommended .
Female reproductive function and fertility may be impaired in patients being treated with OGSIVEO. Impact on fertility may depend on factors including the duration of therapy and the state of gonadal function at the time of treatment. The long-term effects of OGSIVEO on fertility have not been established. Advise patients on the potential risks for ovarian toxicity before initiating treatment with OGSIVEO .
Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.
ALT or AST elevations occurred in 30% and 33% of patients who received OGSIVEO in DeFi, respectively. Grade 3 ALT or AST elevations (> 5 × ULN) occurred in 6% and 2.9% of patients, respectively . Monitor liver function tests regularly and modify dose as recommended .
New non-melanoma skin cancers can occur in patients treated with OGSIVEO. In DeFi, cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively . Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.
Electrolyte abnormalities can occur in patients treated with OGSIVEO. In DeFi, these included decreased phosphate (65%) and decreased potassium (22%). Phosphate <2 mg/dL occurred in 20% of patients who received OGSIVEO. Grade 3 decreased potassium occurred in 1.4% of patients . …
Nirogacestat side effects
The following serious adverse reactions are described elsewhere in the labeling:
Diarrhea
Ovarian Toxicity
Hepatotoxicity
Non-Melanoma Skin Cancers
Electrolyte Abnormalities
Hypersensitivity Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of OGSIVEO was evaluated in 69 patients enrolled in DeFi with progressing desmoid tumor . Patients received OGSIVEO 150 mg orally twice daily or placebo orally twice daily until disease progression or unacceptable toxicity. The median duration of exposure to OGSIVEO was 20.6 months (range: 0.3 to 33.6).
Serious adverse reactions occurred in 20% of patients who received OGSIVEO. Serious adverse reactions occurring in ≥ 2% of patients were ovarian toxicity (4%).
Permanent discontinuation of OGSIVEO due to an adverse reaction occurred in 20% of patients. Adverse reactions which resulted in permanent discontinuation of OGSIVEO in ≥ 2% of patients were diarrhea, ovarian toxicity, increased ALT, and increased AST.
Dosage interruptions of OGSIVEO due to an adverse reaction occurred in 51% of patients. Adverse reactions which required dosage interruption in ≥ 2% of patients included diarrhea, rash, stomatitis, hypophosphatemia, fatigue, folliculitis, nausea, and ovarian toxicity. …
Drug interactions
Strong or Moderate CYP3A Inhibitors
Prevention or Management | Avoid concomitant use of OGSIVEO with strong or moderate CYP3A inhibitors including grapefruit products, Seville oranges, and starfruit.
Clinical Effect | Nirogacestat is a CYP3A substrate. Strong or moderate CYP3A inhibitors increase nirogacestat exposure , which may increase the risk of OGSIVEO adverse reactions.
Strong or Moderate CYP3A Inducers
Prevention or Management | Avoid concomitant use of OGSIVEO with strong or moderate CYP3A inducers.
Clinical Effect | Nirogacestat is a CYP3A substrate. Strong or moderate CYP3A inducers decrease serum nirogacestat exposure , which may reduce the effectiveness of OGSIVEO.
Gastric Acid Reducing Agents
Prevention or Management | Avoid concomitant use with proton pump inhibitors and H2 blockers.
If concomitant use cannot be avoided, OGSIVEO can be staggered with antacids (e.g., administer OGSIVEO 2 hours before or 2 hours after antacid use).
Clinical Effect | Nirogacestat is poorly soluble at pH ≥ 6. Gastric acid reducing agents may decrease serum nirogacestat exposure , which may reduce the effectiveness of OGSIVEO. …
About this medicine
OGSIVEO oral tablets contain nirogacestat (as nirogacestat hydrobromide), a gamma (ɣ) secretase inhibitor. Nirogacestat hydrobromide is chemically known as (S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl) pentanamide dihydrobromide. The empirical formula is C27H43Br2F2N5O and the molecular weight is 651.48 g/mol. Nirogacestat hydrobromide is a white to off white powder with an aqueous solubility of 11.4 mg/mL and a pH of 4.4 in water at 25°C. Nirogacestat dihydrobromide is highly soluble at low pH, however the solubility significantly decreases at pH > 6.0. The molecule has pKa's of 5.77 and 7.13. The structural formula for nirogacestat hydrobromide is:
OGSIVEO (nirogacestat) tablets are immediate release (IR), film-coated tablets intended for oral administration. Each 100 mg tablet contains 100 mg nirogacestat as 133.050 mg nirogacestat hydrobromide. OGSIVEO 100 mg tablets are round, biconvex with an approximate diameter of 10 mm. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f172e6ff-3190-41b0-b95a-58a7ef9e9e1e. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate